98%
921
2 minutes
20
Background: Microaxial circulatory support devices have been used to support patients treated with percutaneous coronary intervention (PCI) for acute myocardial infarction complicated by cardiogenic shock (AMICS). The purpose of this systematic review and meta-analysis was to pool and analyze the existing evidence on the baseline characteristics, periprocedural data, and outcomes of microaxial support before and after PCI in AMICS.
Methods: An electronic database search was performed to identify all cohort studies on Impella and PCI for cardiogenic shock in the English language. A total of five articles comprising 543 patients were included. These patients received microaxial support either before (pre-PCI) or after (post-PCI) undergoing PCI. Comparative analyses were done between both groups.
Results: The mean patient age was 66 years [95% Confidence Interval (58-74)], and 22% (89/396) of patients were female. ST-elevation myocardial infarctions (MI) comprised 64% (44-80) of MIs and 50% (44-56) of MIs involved the left anterior descending artery. The mean number of diseased vessels was 2.21 (1.62-2.80). The mean left ventricular ejection fraction was 31% (23.4-38.6). The mean arterial pressure was 66.3 mm Hg (54.1-78.5). Mean serum lactate [6.1 mmol/L (3.3-8.9)] and serum creatinine [1.4 mg/dl (1.0-1.7)] were similar between groups. 30-day mortality was lower in the pre-PCI group [41% (34%-49%)] compared to the post-PCI group [61% (42%-77%), p < 0.01]. Pooled Kaplan-Meier analysis showed better early survival in the pre-PCI group (p < 0.001).
Conclusion: Patients presenting with AMICS were similar at baseline in both pre-PCI and post-PCI groups. Nevertheless, pre-PCI group showed better early survival compared to post-PCI group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/aor.14494 | DOI Listing |
Front Cardiovasc Med
August 2025
Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita, Japan.
JAMA Cardiol
August 2025
Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Denmark.
Importance: Microaxial flow pump treatment improves survival in selected patients with infarct-related cardiogenic shock; however, treatment carries substantial risks, and benefit may vary by patient subgroup. Systolic blood pressure (SBP) has been proposed as a modifier of the survival benefit.
Objective: To investigate whether SBP at randomization modifies the survival benefit of microaxial flow pump treatment in ST-segment elevation myocardial infarction-related cardiogenic shock.
Future Cardiol
August 2025
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cardiogenic shock (CS) is a complex condition characterized by insufficient cardiac output, tissue hypoperfusion, and life-threatening organ failure. In this review, we describe the definition, pathophysiology, classification, and approach to management in CS. We highlight recent advances in understanding the phenotypic heterogeneity and classification of CS.
View Article and Find Full Text PDFJACC Case Rep
August 2025
Pueblo Cardiology Associates, Pueblo, Colorado, USA.
Background: Thrombolytic therapy is indicated for patients with ST-segment elevation myocardial infarction (STEMI) presenting >120 minutes from a percutaneous coronary intervention-capable facility. Timely transfer is critical in thrombolytic failure.
Case Summary: A 46-year-old woman presented to a rural emergency department with an anterior STEMI.
JACC Cardiovasc Interv
August 2025
Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
The increasing use of microaxial flow pumps (mAFP) underpins the need for a comprehensive approach to manage critically ill patients in an effort to maximize the benefits of this temporary mechanical circulatory support (tMCS) while minimizing its potential complications. Multimodality cardiac imaging offers an irreplaceable array of tools to address device position, device-heart hemodynamic interaction, myocardial recovery assessment, and identification of complications. This review provides a comprehensive and pragmatic summary of the cardiovascular imaging modalities currently available throughout the pathway of care of mAFP-supported patients, from device insertion, to intensive cardiac care hemodynamic monitoring, weaning guidance, and myocardial recovery assessment.
View Article and Find Full Text PDF